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Equine Metabolic Syndrome is a hormonal disorder caused by the prolonged exposure of the body’s tissues to the glucocorticosteroid hormone cortisol.  This situation may be the consequence of adrenal gland over production of cortisol due to an imbalance of the hypothalamic-pituitary-adrenal (HPA) axis.  Horses that have Equine Metabolic Syndrome or exhibit Equine Metabolic Syndrome- like symptoms generally have higher concentrations of cortisol in their peripheral circulation.

Cortisol is a glucocorticosteroid hormone, the synthesis and secretions of which is triggered by stress.  The HPA axis is critical in maintaining physiological homeostasis.  Cortisol stimulates gluconeogenesis and it has profound regulatory effects on numerous physiological systems.  Chronic activation of the HPA axis due to extended exposure to stress causes an increase in glucocorticosteroid production from the adrenal cortex and catecholamine production from the adrenal medulla.  Glucocorticosteroids prevent or suppress functions of the mammalian immune system (Bauer, 2005; Chrousos, 1995).  Increased concentrations of glucocorticosteroid hormones allow pathogens to more readily establish an infection (Chrousos, 1995).

_______________
This thesis follows the style of The Journal of Animal Science.

As horses with Equine Metabolic Syndrome have higher secretions of cortisol, it is now 
important to determine the effect of prolonged exposure of the equine immune system to 




Equine Metabolic Syndrome is a hormonal disorder caused by the prolonged exposure of the body’s tissues to cortisol, also referred to as hypercortisolism and Cushing’s syndrome.  The tissue’s prolonged exposure to cortisol is due to an imbalance of the hypothalamic-pituitary adrenal (HPA) axis, causing an increase in secretion of adrenocorticotropin (ACTH).  The ACTH produced is semiautonomous and resets the HPA feedback; therefore, ACTH is still secreted in the presence of abnormally high levels of cortisol.  Some horse and pony breeds are genetically predisposed to metabolic syndrome (Johnson, 2002).  

Horses affected with this Metabolic Syndrome are usually between eight and twenty years of age and characterized as obese. Distinct excess body fat of these horses is distributed around the neck and haunches.  Brood mares exhibit irregular estrous cycles, and as a result, are extremely difficult to breed.  Geldings affected with Equine Metabolic Syndrome tend to develop swollen sheaths as a result of enhanced subcutaneous adiposity.  In comparison to horses, ponies readily deposit fat around the neck and haunches, consequently leaving them more susceptible to laminitis.  It is shown that ponies are more glucose intolerant than horses (Field and Jeffcott, 1989).  Glucose intolerance is defined as delayed hypoglycemia after an intravenous, oral glucose load, or following a grain meal, because peripheral tissues or the liver are insensitive to insulin action.  Horses that have Equine Cushing’s Syndrome or exhibit Cushing-like symptoms have higher concentrations of cortisol circulating throughout their system.  With the naturally high levels of cortisol, stressors do not need to be applied in order to achieve the disruption of the HPA axis, making them a unique model to measure the effect of prolonged exposure to glucocorticosteroids on the immune system.

Stress and Cortisol
Cortisol is a glucocorticosteroid that is synthesized by the zona fasciculata of the adrenal cortex.   Glucocorticosteroids enhance the action of hormones on body tissues and are essential in metabolic regulation during periods of injury and stress (Gerrard et al., 1985).  Cortisol is regulated by the hypothalamic-pituitary-adrenal (HPA) axis.  The hypothalamus secretes corticotrophin releasing hormone (CRH), which acts on the pituitary, causing the pituitary to release adrenocorticotropin (ACTH).  ACTH stimulates the adrenocortical cells to secrete cortisol, which diffuses into the blood stream and is carried throughout the body.  A dysregulation in the HPA axis causes an increase in concentration of ACTH, consequently increasing cortisol concentrations.

Stress is a disruption of physiological homeostasis caused by environmental events and conditions.  There are two glucocorticosteroid actions: modulating actions and preparative actions.  Modulating actions alter an organism’s response to a stressor, while preparative actions alter an organism’s response to a subsequent stressor, or aid in adapting to chronic stressors (Sapolsky et al., 2000).  The response to the application of a stressor is mediated by the endocrine system.  When responding to a stressor, the first wave is quick, lasting only seconds.  Secretion of epinephrine and norepinephrine is increased from the Sympathetic Nervous System.  The hypothalamus also acts acutely by releasing CRH into portal circulation causing the pituitary to enhance ACTH (Sapolsky et al., 2000).  The second wave of the endocrine response to a stressor is long, lasting several minutes.  It involves steroid hormones and a decrease in gonadal secretion as a result of stimulated glucocorticosteroid secretion (Sapolsky et al., 2000).  

Immunity
Immunity is an animal’s ability to ward off foreign matter such as bacteria, fungi and infectious microbes.  Both the innate and adaptive immune systems form two different systems of immunity.  Innate immunity is the body’s first response to foreign matter (Chaplin, 2006).  Its germ line includes the skin, phagocytes, neutrophils, natural killers and cytokines (Gaylean et al., 1999).  Adaptive immunity is more complex than innate immunity and requires that the antigen first be recognized and processed.   Adaptive immunity is introduced by the body’s recognition of antigens and responds through vaccinations, lymphocytes, and antibodies.  Adaptive, or acquired, immunity is further divided into humoral and cell mediated immunity, where cell mediated immunity requires that T-lymphocytes provide defense against intracellular pathogens (Gaylean et al., 1999).  Humoral immunity is driven by B-lymphocytes that respond to antigens and become antibody producing cells and memory cells (Gaylean et al., 1999).  

Stress and the Immune System







In Vitro Study of the Effect of DEX and RU486 on Lymphocyte Proliferation and Immunoglobulin Production
Peripheral blood sample was obtained from seven normal horses to isolate lymphocytes. To do this, approximately 20 mL of blood was collected from each horse via jugular venipuncture into EDTA-coated vacutainer tubes.  Samples were placed on ice and transferred back to the lab.  The red blood cells were lysed, with the intention of getting rid of contaminants, and the lymphocytes were isolated.  Seven mL of blood were layered over 5 mL of Ficoll-Plaque and centrifuged at 4○ C and 1000G for 25 minutes.  The lymphocyte layer were removed with a sterile 5- mL pipette and transferred to a clean 15- mL tube.  HBSS was added to the 14 mL mark, and the sample centrifuged again at 200G for 10 minutes.  The supernatant was aspirated, and 2 mL of 0.2% NaCl quickly added for trituration, then an additional 2 mL of 1.6% NaCl was added.  Again, HBSS was added to the 14 mL marker of the tube, and then centrifuged at 200G.  The supernatant was aspirated and the cell pellet re-suspended in 1 mL of culture medium and diluted with 20 µL for determination of cell number.  Treatments consisted of serial dilutions (ranging from 0.16-to-10 ug/ml) of the blastogenic mitogen Concanavlin (ConA, lot# 033K8936, Sigma-Aldrich, St. Louis, MO).  Treatments and cell suspension were added to the wells to yield a total volume of 100 μL and a final concentration of 1x105 cells/well.  Treatment groups consisted of medium alone (control), increasing doses of ConA, DEX (ranging from 0.001-to-1 uM), RU486 ((ranging from 0.001-to-1 uM) and appropriate combinations of ConA, DEX and RU486.  Cells were incubated at 37o C, 5% CO2, and 50% relative humidity for 92 hrs.  Media was harvested to determine IgM concentrations, and cell proliferation rate was determined as noted below.

In Vitro Comparison of Lymphocyte Proliferation and Immunoglobulin Production in Horses with Normal Concentrations of Cortisol and in Horses with consistently High Concentrations of Cortisol (e.g., Horses with Equine Metabolic Syndrome).
Peripheral blood sample was obtained from seven normal horses and from six horses with metabolic syndrome to determine if abnormally high concentrations of endogenous cortisol adversely affect lymphocytes.  Peripheral blood samples were taken once from each horse to determine their endogenous concentration of cortisol.  Lymphocytes were isolated from horses with either normal and abnormally high concentrations of cortisol.  The ability of these cells to proliferate and to produce IgM in response to the blastogenic mitogen Concanavlin (ConA) were contrasted  in vitro to assess to what degree, if any, that high endogenous concentration of cortisol affects immune functions.  Specifically, cells were treated with media alone or increasing doses of ConA (ranging from 0.16-to-10 ug/ml) to determine proliferation rate.  Medium concentration of IgM were also determined. 

Proliferation- CellTiter96
Once the cells were isolated, they were transferred to a 96-well microtiter incubation plate.  The plate was put into a 5% CO2 humidified incubator for 92 hours.  After the 92- hour period, 15 µL dye solution was added to each well, and the plate incubated for another four hours at 37○ C.  A STOP solution was added to each well and incubated at room temperature for one hour.  Absorbance was recorded at 570 nm with a reference wavelength of 630-750 nm.  

Statistical Analysis































Effect of Treatments Pertaining to Equine Lymphocyte Proliferation 
Lymphocytes were incubated in medium alone (DMEM/F12 1:1), medium containing Concanavalin A (0-to-5 µg/mL), 1 µM of DEX, 1 µM of RU486, and specific combinations of these factors as depicted by the appropriate figure legend.   Conconavalin A (ConA) caused a dose dependent increase in lymphoproliferation (P<.001; Figure 2).   Lymphocyte proliferation increased as the concentration of ConA in the medium ranged from 0-to-5 µg/mL.  At a concentration of 0 µg/mL of ConA, the mean basal stimulation index was 1.207 and increased by 2.56-fold to have a stimulation index of 3.092 when the medium concentration of ConA was 5 µg/mL.  

Dexamethasone (DEX) is a synthetic glucocorticosteroid that is antagonistic to cellular proliferation.  DEX is a synthetic form of the endogenous glucocorticosteroid hormone cortisol.  In vitro, it behaves as cortisol would in vivo, suppressing immune function by decreasing the number of lymphocytes produced.  A constant concentration of DEX, 1 µM, was added to varying concentrations of ConA.  The addition of DEX to cell culture medium containing ConA decreased lymphocyte proliferation by 21.7% (P<.0001; Figure 3).  Specifically, it decreased basal proliferation by 20.2%, and at ConA concentrations of 0.3125 µg/mL and 5 µg/mL by 31.7% and 23.9% respectively.

RU486 is synthetic antiglucocorticosteroid that negates the negative effects of DEX.  In the presence of ConA, RU486 allows for the further expression of cell proliferation (Nordeen et. al, 1993).  RU486 coupled with ConA outperformed cellular proliferat



















of ConA alone, except at a basal concentration of ConA of 0 µg/mL, where ConA had a higher stimulation index than RU486.  At ConA concentrations of 0.3125 and 5 µg/mL, RU486 had higher proliferation percentages than ConA alone of 17.0 and 13.1 respectively.  

As displayed in Figure 3, DEX suppresses lymphocyte proliferation, and as shown in Figure 4, RU486 increases lymphocyte proliferation at concentrations of ConA above o µg/mL.  The next study was performed to see if RU486 could counteract the suppressive action of DEX on proliferation.  Addition of equivalent concentrations of RU486 and DEX (1 µg/mL) were added to varying concentrations of ConA (0-to-5 µg/mL), in medium containing equine lymphocytes.  The addition of RU486 was able to overcome the inhibitory action of DEX (P<.0001; Figure 5).  

Specifically, RU486 overcame the suppressive effects of DEX and increased basal proliferation by 6.4%.  At 0.3125 µg/mL, ConA coupled with RU486 and DEX increased proliferation by 4.5%, whereas DEX reduced proliferation at the same concentration by 34.4%.  When DEX alone is compared to DEX and RU486 combined together in one treatment at a concentration of 0.3125 µg/mL, proliferation was increased 1.6 fold.  Also, at a concentration of 5 µg/mL, RU486 coupled with DEX overcame the suppressive action of DEX by 21.3%; however, it was not able to stimulate as much proliferation as the cells in medium and ConA alone (absent of RU486 and

















DEX).  This indicates that RU486 is capable of counteracting the suppressive action of DEX on cellular production, allowing the body to produce lymphocytes. 

Effect of In Vitro Treatments in Non-Cushing’s-like Horses
Figures 2-to-5 illustrate the effects the in vitro treatment of lymphocyte proliferation on both Non-Cushing’s-like and Cushing’s-like horses.  The effect of DEX and RU486 on Non-Cushing’s- like horses was also assessed.  The trends are very similar to those previously stated.  









Endogenous levels of cortisol in Non-Cushing’s-like horses is assumed to be at physiologic, non-detrimental concentration, allowing for the observation that when a synthetic form of cortisol (DEX) is added to the in vitro blood sample attained from horse, cellular proliferation is decreased.  Lymphocyte proliferation was decreased by 19.2% at basal concentrations.  At concentrations of 0.3125 and 5 µg/mL, DEX reduced proliferation by 39.9% and 15.3% respectively.  The suppression of proliferation by DEX in vitro is indicative of the suppression of proliferation by endogenous cortisol, which can have a negative impact on immune function by decreasing the body’s capability of producing lymphocytes to ward off infection.  

































Effect of In Vitro Treatments in Cushing’s-like Horses
Equine Metabolic Syndrome is a hormonal disorder caused by the prolonged exposure of the body’s tissues to the glucocorticosteroid hormone cortisol.  This situation may be the consequence of adrenal gland over production of cortisol due to an imbalance of the hypothalamic-pituitary-adrenal (HPA) axis.  Horses that have Equine Metabolic Syndrome or exhibit Equine Metabolic Syndrome- like symptoms generally have higher concentrations of cortisol in their peripheral circulation.  Treatments were applied to lymphocytes obtained from these horses, and the effects were observed.
Cushing’s-like horses also displayed a similar ConA induced, dose-dependent increase in proliferation (P<.0001; Figure 9).






DEX and RU486 were added to cells cultured from Cushing’s-like horses.  As previously stated, Cushing’s-like horses already have higher concentrations of 


































Comparison of Lymphocyte Proliferation in Non-Cushing’s-like vs. Cushing’s-like Horses
In the presence of ConA, lymphocyte proliferation from Cushing’s-like and Non-Cushing’s-like horses was compared.  It was hypothesized that normal horses would have higher levels of proliferation than Cushing’s like horses; however, Cushing’s-like horses had higher stimulation indices than Non-Cushing’s-like horses (Figure 12).  At a concentration of 0 µg/mL, Cushing’s-like horses proliferated 8.3% more than Non-Cushing’s-like horses.  At concentrations of 0.625 and 5 µg/mL, Cushing’s-like horses had higher levels of proliferation (18.1 and 15.1% respectively) than non-Cushing’s-like horses.  While Cushing’s-like horses have higher levels of lymphocyte proliferation than Non-Cushing’s-like horses, they may not be producing adequate amounts of antibodies to be able to sufficiently ward of potential pathogens.  
 

At lower concentration levels (0-to-0.625 µg/mL), Cushing’s-like horses had higher proliferation levels in the presence of DEX, while at higher ConA concentration levels (1.25-5 µg/mL), non-Cushing’s-like horses had higher proliferation levels than Cushing’s-like horses (Figure 13).  A noted feature of this study is the decrease in lymhoproliferation at a ConA concentration of 0.3125 µg/mL.  The additional amounts of glucocorticosteroids added to the already present high levels of cortisol in the Cushing’s-like horses accounts for the lower levels of proliferation at higher concentrations of ConA.  With higher concentrations of cortisol already present in the 





















peripheral blood system, the HPA axis is potentially deregulated.  An abnormality in the regulation of the HPA axis, like chronic activation of the axis due to stress, can lead to an increase in glucocorticosteroid (cortisol) production.  Cortisol is bound by glucocorticoreceptors resulting in an interference with the regulation of cytokine producing immune cells (NF-KB).  Concentrations of cortisol achieved during periods of stress are known to inhibit lymphocyte proliferation and suppress the secretion of certain cytokines (Chrousos, 1995).  The addition of the synthetic form of cortisol (DEX), to the already high concentrations of endogenous cortisol, increased the available glucocorticosteroid hormones to be bound to receptors on lymphocytes.  This increase in binding further reduces lymphocyte proliferation, resulting in the supplementary reduction of cytokine secretion.  The lymphocytes, although in the presence of increased concentrations of a proliferative stimulant, were not able to increase proliferation due to the competitive binding of glucocorticosteroids.  Therefore the concentration of glucocorticosteroids must have been greater than that of ConA, to prevent proliferation, whereas the non-Cushing’s-like horses did not have excessive amounts of glucocorticosteroids present, which accounts for their ability to proliferate more than the Cushing’s-like horses.  

Equivalent amounts of DEX and RU486 (1 µg/mL) were added to medium containing equine lymphocytes and varying amounts of ConA.  Lymphocyte proliferation of non-Cushing’s-like horses was greater than that of Cushing’s-like horses (Figure 14).  At a basal concentration of Con A (0 µg/mL), lymphoproliferation was 36.6% greater in non










Cushing’s-like horses.  At concentrations of 0.3125 and 5 µg/mL, lymphoproliferation 
was greater in non-Cushing-like horses by 24.5 and 18.9 % respectively.  The absence of a proliferative stimulant allows for only endogenous hormones to induce proliferation.  Higher concentrations of cortisol are present in Cushing’s-like horses, resulting in suppression of lymphoproliferation.  RU486 competes with DEX for binding sites on the intracellular glucorticoid receptor (Garzo et al., 1988).   RU486 was only able to counteract the negative effects of DEX and cortisol by competitively binding with already high concentrations of endogenous cortisol.    However, RU486 was able to counteract the negative effects of glucocorticodteroids and increase stimulation above that of DEX with ConA and lymphocytes.



































Cortisol is a glucocorticosteroid that is triggered by stress and is produced from the adrenal cortex, resulting in increased blood pressure and suppressed immune system function.  The depression of the immune system disables the body from properly warding off infection, greatly compromising the horse’s health.  Understanding how the immune system is compromised is imperative in order to make advances to overcome this problem.  It has been shown that endogenous cortisol and its synthetic counterpart, DEX, suppress the immune system, decreasing the production of lymphocytes, therefore decreasing the amount of antibody produced, resulting in depression of immune function.  This study has illustrated the ability of RU486 to overcome the detrimental effects of DEX.  By preventing DEX from binding glucocorticoid receptors, RU486 stabilizes the complex, preventing the suppression of lymphocytes, and enhancing the action of agonists.  In the presence of RU486, the capability of lymphocytes exposed to higher levels of endogenous cortisol to proliferate more than lymphocytes out of horses that were not exposed to high concentrations of endogenous cortisol presents an interesting area for further research.  A possible explanation for this may be that while horses with high concentrations of endogenous cortisol have higher lymphoproliferation levels, the lymphocytes may not be producing enough antibodies in order to properly defend the immune system.  The enhanced simulative effects of RU486 give rise to interesting areas that allow for further research.  
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1.	Media contained DME/F12 + 10%  Heat Inactivated Fetal Bovine Serum + 1X Penn-Strep + 1 X L-Glutamine + 10 µM BME.
a.	For a 50 mL mix
i.	44 mL of DME/F12


















2.	Label 4 sets of 8- 15 mL conical tubes (orange tops).
a.	ConA  H  A/  [high] [low]
b.	ConA + Dex  H  A/  [high] [low]
c.	ConA + RU486 H  A/  [high] [low]
d.	ConA + Dex + RU486 H  A/  [high] [low]
3.	Thaw FBS, P/S, and L-Glutamine in a water bath at 37oC.  Vortex.
4.	Make proliferation media.












Dose (Tube Lable)	Volume of Media	Volume of ConA	Concentration in media	Final Concentration in well
H	1.96 mL	40 µL	20 µg/mL	10 µg/mL
G	1 mL	1 mL from tube H	10 µg/mL	5 µg/mL
F	1 mL	1 mL from tube G	5 µg/mL	2.5 µg/mL
E	1 mL	1 mL from tube F	2.5 µg/mL	1.25 µg/mL
D	1 mL	1 mL from tube E	1.25 µg/mL	0.625 µg/mL
C	1 mL	1 mL from tube D	0.625 µg/mL	0.3125 µg/mL
B	1 mL	1 mL from tube C	0.3125 µg/mL	0.15625 µg/mL
A	1 mL	0 mL	0 µg/mL	0 µg/mL

6.	Make Dex and RU486 doses.
a.	Romve 4 µL of ConA/media solution from all 8 “Dex” labeled tubes.  Add 4 µL of Dex to each tube.
b.	Romve 4 µL of ConA/media solution from all 8 “RU486” labeled tubes.  Add 4 µL of RU486 to each tube.
c.	 Romve 8 µL of ConA/media solution from all 8 “Dex + RU486” labeled tubes.  Add 4 µL of Dex to each tube and 4 µL of RU486 
7.	Plate media 50 µL per well in 3 replicates ([0 µg]A  [20 µg]H).  




















ISOLATION OF PBMC’S AND PROLIFERATION PROTOCOL

9.	Collect equine blood in six 10 ml plasma EDTA vaccutainers (purple top).  Place on ice.
10.	Add 5 ml of Ficoll Paque to seven sterile 15 ml conical tubes.  Layer about 7 ml of blood very slowly on top of the Ficoll Paque.  Do not allow the blood and the Ficoll to mix.
11.	Centrifuge at 1000xg for thirty minutes.
12.	Using a sterile 10 ml pipette, very carefully, remove the buffy coat layer (try not to aspirate off any of the red blood cell layer) and transfer and transfer to a clean 50 ml conical tube.  Add 1X HBSS to the 40 ml mark on the 50 ml conical.  Centrifuge at 200 xg for 10 minutes.
13.	Aspirate supernatant (leaving the white blood cell pellet).  Add 2 ml of 0.2% NaCl, triturate to brak up the cell pellet.  Lyse cells for no more than 1 minute.  Add 2 ml of 1.6% NaCl.  Add 1X HBSS to the 40 ml mark on the 50 ml conical.  Centrifuge at 200 xg for 10 minutes.
14.	If you still have red blood cell contamination, repeat step 5.  If not:
15.	Aspirate supernatant and re-suspend cell pellet in 1 ml of media.
16.	Remove 10 µL of cells and count in 90 µL of trypan blue using a hemacytometer.
17.	Dilute cells to desired concentration in 50 µL and transfer to a 96-well plate using a multichannel pipette.   Final volume in all wells will be 100 µL (including doses).
18.	Incubate in a 37o C humidified incubator with 5% CO2 for 92 hours.
19.	Add 15 µL of Dye solution (Promega Cell Titer 96 Non-Radioactive Cell Proliferation Assay) to all wells of the plate designated for proliferation.  Return to the incubator for 4 hours.
20.	Add 100 µL of Solubilization/Stop solution to all wells.  Incubate at room temperature overnight.  Read absorbance at 570 nm with a reference wavelength of 630-750 nm.
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